OAMU
UTHR icon

Ostrum Asset Management US’s United Therapeutics UTHR Stock Holding History

Ostrum Asset Management US’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,758
Closed -$518K – 215
2018
Q4 		$518K Buy
+4,758
New +$552K 0.08% 148

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ostrum Asset Management US's UTHR Position: Q1 2019 in Review

Ostrum Asset Management US sold out of United Therapeutics (UTHR) in Q1 2019, closing a stake of 4,758 shares — an estimated $518K sold.

Ostrum Asset Management US first reported a position in UTHR in Q4 2018 and held it in 1 quarter. The position peaked at $518K in Q4 2018. 378 funds tracked by Wall St. Rank hold UTHR as of Q1 2019.

  • Ostrum Asset Management US reported no remaining United Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ostrum Asset Management US sold 4,758 United Therapeutics shares in Q1 2019, an estimated $518K.
  • Ostrum Asset Management US first reported a position in United Therapeutics in Q4 2018 and held it in 1 quarter.
  • Ostrum Asset Management US's United Therapeutics position peaked at $518K in Q4 2018.
  • 378 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2019.

Based on Ostrum Asset Management US's 13F filing for Q1 2019, filed 15 May 2019.